DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition.
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition.
DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functional status on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 13, 2022 | Debt Financing | €20M | 1 |
![]() |
— | Detail |
Oct 20, 2022 | Series B | €13M | 5 |
![]() |
— | Detail |
Jul 7, 2020 | Series A | €3.50M | 2 |
![]() ![]() |
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Debt Financing |
![]() |
Yes | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |